Amit Choudhary
Co-Founder

Photys Therapeutics utilizes a proprietary platform of bifunctional small molecules to precisely control protein post-translational modifications, enhancing the phosphorylation of target proteins. This technology aims to restore protein function and amplify disease-fighting mechanisms, addressing the challenges of dysfunctional protein signaling in various diseases.
Raised to date
$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.


Co-Founder
Many diseases are characterized by dysfunctional protein signaling due to impaired post-translational modifications. Current therapeutic approaches often fail to restore normal protein function and leverage the body's natural disease-fighting mechanisms.
Photys Therapeutics develops bifunctional small molecules that precisely control protein post-translational modifications, specifically enhancing protein phosphorylation. Their Phosphorylation-Inducing Chimeric Small Molecules (PHICS) platform induces proximity between specific kinases and target proteins, modulating key protein functions by enabling precise phosphorylation at native or non-native sites. This approach aims to restore protein function, repair signaling pathways, and amplify endogenous disease-fighting mechanisms. By going beyond protein degradation, Photys' technology offers a novel way to address diseases driven by dysfunctional protein signaling.
The primary target audience includes researchers and pharmaceutical companies focused on developing therapies for diseases characterized by dysfunctional protein signaling.